Phase I/II trial of samarium SM-153 lexidronam combined with docetaxel for patients with androgen-independent prostate cancer
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Docetaxel; Prednisone; Samarium-153-SM-lexidronam
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cytogen Corporation
- 14 Jun 2007 Status change
- 06 Jun 2007 Preliminary results on 10 patients reported at ASCO.
- 05 Dec 2005 New trial record.